Safety assessment of potential probiotic lactic acid bacteria strains Pediococcus acidilactici SY21 and Pediococcus acidilactici SY22

对潜在益生菌乳酸菌菌株Pediococcus acidilactici SY21和Pediococcus acidilactici SY22的安全性评估

阅读:8
作者:Jaein Shin ,Huijin Jeong ,Na-Kyoung Lee ,Dae-Kyung Kang ,Hyun-Dong Paik ,Young-Seo Park

Abstract

Pediococcus acidilactici SY21 and Pediococcus acidilactici SY22 exhibit anti-inflammatory activity; however, their safety has not been evaluated. The suitability as probiotic strains were evaluated by using phenotypic and genotypic analyses. Indole production, urease activity, mucin degradation, bile salt hydrolase activity, β-hemolysis, and gelatin liquefaction activity were not found. The minimum inhibitory concentrations of the nine antibiotics tested were below the cut-off values recommended by the European Food Safety Authority, except for kanamycin and clindamycin in P. acidilactici SY21 and kanamycin in P. acidilactici SY22. After confirming that the genetic basis of antibiotic resistance exceeded the cut-off value, all isolates showed intrinsic resistance. P. acidilactici SY21 and P. acidilactici SY22 did not produce biogenic amine, and β-glucuronidase activity. Neither strain was cytotoxic to Caco-2 cells. Antibiotic resistance or virulence genes were not detected with whole-genome sequencing. This study demonstrated the safety of the P. acidilactici SY21 and P. acidilactici SY22 strains as probiotics. Supplementary information: The online version contains supplementary material available at 10.1007/s10068-025-01925-9. Keywords: Anti-inflammatory; Antibiotic resistance; Pediococcus acidilactici; Probiotics; Safety assessment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。